$254 Million is the total value of EcoR1 Capital, LLC's 32 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 56.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC | $31,778,000 | +40.9% | 2,430,451 | +17.9% | 12.53% | +59.0% |
| GLPG | Buy | GALAPAGOS NVsponsored adr | $24,373,000 | +136.2% | 439,385 | +78.1% | 9.61% | +166.6% |
| RTRX | RETROPHIN INC | $21,819,000 | +30.4% | 1,225,084 | 0.0% | 8.60% | +47.1% | |
| CYTK | Buy | CYTOKINETICS INC | $20,306,000 | +40.3% | 2,139,697 | +4.2% | 8.01% | +58.3% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $16,335,000 | +55.1% | 2,943,164 | +40.3% | 6.44% | +75.0% |
| FGEN | Sell | FIBROGEN INC | $12,943,000 | -29.6% | 788,745 | -8.7% | 5.10% | -20.6% |
| XLRN | Buy | ACCELERON PHARMA INC | $12,620,000 | +76.9% | 371,381 | +37.4% | 4.98% | +99.7% |
| GILEAD SCIENCES INCcall | $12,513,000 | -9.2% | 150,000 | 0.0% | 4.93% | +2.5% | ||
| New | ALLERGAN PLCcall | $11,555,000 | – | 50,000 | +100.0% | 4.56% | – | |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $9,509,000 | – | 244,950 | +100.0% | 3.75% | – |
| DERM | New | DERMIRA INC | $7,956,000 | – | 272,000 | +100.0% | 3.14% | – |
| EPZM | Sell | EPIZYME INC | $7,732,000 | -60.1% | 755,046 | -52.8% | 3.05% | -55.0% |
| Buy | IRONWOOD PHARMACEUTICALS INCcall | $7,606,000 | +131.7% | 581,500 | +93.8% | 3.00% | +161.5% | |
| KURA | KURA ONCOLOGY INC | $6,681,000 | -33.1% | 2,465,286 | 0.0% | 2.63% | -24.5% | |
| NTLA | New | INTELLIA THERAPEUTICS INC | $6,633,000 | – | 310,695 | +100.0% | 2.62% | – |
| AKAOQ | New | ACHAOGEN INC | $5,957,000 | – | 1,571,708 | +100.0% | 2.35% | – |
| BGNE | Buy | BEIGENE LTDsponsored adr | $5,226,000 | +1031.2% | 175,380 | +1012.4% | 2.06% | +1180.1% |
| KIN | KINDRED BIOSCIENCES INC | $5,072,000 | +2.6% | 1,432,765 | 0.0% | 2.00% | +15.8% | |
| NBRV | Sell | NABRIVA THERAPEUTICS AGsponsored adr | $4,221,000 | -33.4% | 562,741 | -20.5% | 1.66% | -24.9% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $3,520,000 | -48.3% | 357,365 | -30.0% | 1.39% | -41.6% |
| COLL | Sell | COLLEGIUM PHARMACEUTICAL INC | $3,339,000 | -61.1% | 281,776 | -40.4% | 1.32% | -56.1% |
| XNCR | New | XENCOR INC | $3,190,000 | – | 168,000 | +100.0% | 1.26% | – |
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $3,018,000 | -57.3% | 136,882 | -43.1% | 1.19% | -51.8% |
| EDIT | Sell | EDITAS MEDICINE INC | $2,085,000 | -31.3% | 85,469 | -2.8% | 0.82% | -22.5% |
| ARRAY BIOPHARMA INCcall | $1,851,000 | +20.7% | 520,000 | 0.0% | 0.73% | +36.2% | ||
| FWP | Sell | FORWARD PHARMA A/Ssponsored adr | $1,532,000 | -7.1% | 84,332 | -13.1% | 0.60% | +4.9% |
| IMMUNOGEN INCcall | $922,000 | -63.9% | 299,500 | 0.0% | 0.36% | -59.2% | ||
| AKTX | Sell | AKARI THERAPEUTICS PLCsponsored adr | $856,000 | -33.7% | 63,468 | -31.2% | 0.34% | -25.1% |
| TSRO | New | TESARO INC | $773,000 | – | 9,200 | +100.0% | 0.30% | – |
| ADXS | New | ADVAXIS INC | $751,000 | – | 92,800 | +100.0% | 0.30% | – |
| TARGACEPT INCnote | $669,000 | 0.0% | 669,166 | 0.0% | 0.26% | +12.8% | ||
| EIGR | Sell | EIGER BIOPHARMACEUTICALS INC | $281,000 | -91.2% | 14,190 | -92.5% | 0.11% | -90.0% |
| Exit | ZAFGEN INCcall | $0 | – | -10,000 | -100.0% | -0.02% | – | |
| ONCE | Exit | SPARK THERAPEUTICS INC | $0 | – | -8,700 | -100.0% | -0.09% | – |
| LIFE | Exit | ATYR PHARMA INC | $0 | – | -74,959 | -100.0% | -0.10% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INC | $0 | – | -28,032 | -100.0% | -0.16% | – |
| Exit | CYTOKINETICS INCcall | $0 | – | -250,000 | -100.0% | -0.62% | – | |
| LOXO | Exit | LOXO ONCOLOGY INC | $0 | – | -150,308 | -100.0% | -1.44% | – |
| FLKS | Exit | FLEX PHARMA INC | $0 | – | -575,925 | -100.0% | -2.21% | – |
| KITE | Exit | KITE PHARMA INC | $0 | – | -150,000 | -100.0% | -2.41% | – |
| AIMT | Exit | AIMMUNE THERAPEUTICS INC | $0 | – | -521,366 | -100.0% | -2.47% | – |
| CPXX | Exit | CELATOR PHARMACEUTICALS INC | $0 | – | -950,000 | -100.0% | -3.66% | – |
| Exit | SPDR SERIES TRUST S&P BIOTECHcall | $0 | – | -297,200 | -100.0% | -5.36% | – | |
| Exit | ARRAY BIOPHARMA INCnote | $0 | – | -22,534,000 | -100.0% | -6.34% | – | |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -500,757 | -100.0% | -7.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.